ABCC7 p.Lys593*
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 10748197
[PubMed]
Cahill P et al: "Identification of the cystic fibrosis transmembrane conductance regulator domains that are important for interactions with ROMK2."
No.
Sentence
Comment
53
These experiments were performed on oocytes expressing ROMK2/CFTR-K593X and ROMK2/CFTR-D835X and showed that the current was Ba2ϩ -sensitive Kϩ current and not stimulated Cl- current.
X
ABCC7 p.Lys593* 10748197:53:66
status: NEW58 CFTR Constructs and Method of Mutagenesis-Cells were injected with ROMK2 alone, ROMK2/CFTR-WT, ROMK2/SUR, ROMK2/CFTR-D835X (a CFTR construct with an intact nucleotide binding fold and a functional R domain), ROMK2/CFTR-K593X (a CFTR construct with an intact nucleotide binding fold but no R domain), or ROMK2/ RT2N2CFTR (a CFTR construct containing the R domain, the second nucleotide binding fold domain, the second transmembrane domain, and the first 159 bases of CFTR-WT so as to include the Kozak methionine for translation initiation) (Fig. 1).
X
ABCC7 p.Lys593* 10748197:58:219
status: NEW61 The oligonucleotides used for mutagenesis were CFTR-K593X, 5Ј-CTGTTAACTGATGGCT- AGCAAACTAGG-3Ј and CFTR-D835X, 5ЈCACGAAAAGTGTCACTGG- CCCCTCAGGCAAACTTCGATATATTACTGTCCACAAGAGCTTAAT- TTTGTGC-3Ј.
X
ABCC7 p.Lys593* 10748197:61:52
status: NEW65 CFTR-D835X and CFTR-K593X are expressed at membrane level, in varying expression systems (9, 19).
X
ABCC7 p.Lys593* 10748197:65:20
status: NEW76 When ROMK2 was co-expressed with a CFTR construct containing transmembrane domain 1 and NBF1 without an R domain (CFTR-K593X) and exposed to FSK/IBMX, the resultant Ba2ϩ -sensitive Kϩ current was inFIG. 1.
X
ABCC7 p.Lys593* 10748197:76:119
status: NEW77 Schematic representation of CFTR-WT (A), RT2N2CFTR (B), a CFTR mutant containing the R domain, transmembrane domain 2, NBF2, and the initial 159 bases of CFTR-WT so as to include the Kozak methionone for translation initiation, CFTR-K593X (C), a CFTR mutant truncated at residue 593, with an intact NBF1 and CFTR-D835X (D), a CFTR mutant truncated after the R domain.
X
ABCC7 p.Lys593* 10748197:77:233
status: NEW81 Without cAMP stimulation glibenclamide inhibited 46 Ϯ 4.5% (n ϭ 6) of Kϩ current when ROMK2 and CFTR-K593X were co-expressed, which is similar to previous findings.
X
ABCC7 p.Lys593* 10748197:81:119
status: NEW84 Furthermore, after cAMP stimulation there is a significant enhancement of glibenclamide effect on ROMK2/CFTR-K593X currents (Table I).
X
ABCC7 p.Lys593* 10748197:84:109
status: NEW92 However, in contrast to the ROMK2/CFTR-K593X currents, glibenclamide inhibition is not enhanced after cAMP stimulation.
X
ABCC7 p.Lys593* 10748197:92:39
status: NEW96 Conditions that promote phosphorylation did not alter the glibenclamide insensitive FIG. 2. Effect of glibenclamide on whole cell Ba2ϩ -sensitive Kϩ currents for ROMK2 when co-expressed with CFTR-D835X, CFTR-K593X, or RT2N2CFTR under basal conditions (in the absence of FSK/IBMX) (A, B, and E) in Xenopus oocytes, using two-microelectrode voltage clamp techniques.
X
ABCC7 p.Lys593* 10748197:96:220
status: NEW103 A representative family of whole cell currents from oocytes injected with either ROMK2/CFTR-D835X or ROMK2/ CFTR-K593X, and traces under basal conditions (in the absence of FSK/IBMX) and after stimulation with FSK/IBMX (100 M/1 mM) are compared.
X
ABCC7 p.Lys593* 10748197:103:113
status: NEW105 It demonstrates that in ROMK2/ CFTR-K593X-injected oocytes, glibenclamide inhibition of whole cell Kϩ current remains prominent, despite application of FSK/IBMX, but that in ROMK2/CFTR-D835X-injected oocytes the FSK/IBMX mixture attenuates this inhibitory response.
X
ABCC7 p.Lys593* 10748197:105:36
status: NEW121 e p value Ͻ0.05 when comparing % glibenclamide inhibition of whole cell Kϩ current under basal conditions and after stimulation with FSK/IBMX for R2/K593X where there is a marked enhancement of inhibitory response with FSK/IBMX.
X
ABCC7 p.Lys593* 10748197:121:161
status: NEW122 FIG. 4. Effect of glibenclamide on Ba2؉ -sensitive currents obtained from Xenopus oocytes using two-microelectrode voltage clamp techniques. Summary of data obtained for ROMK2, ROMK2/ CFTR-WT, ROMK2/CFTR-D835X, ROMK2/CFTR-K593X, and ROMK2/SUR, as indicated on the x axis. Represented on the y axis is the percentage of total barium-sensitive Kϩ current inhibited by glibenclamide.
X
ABCC7 p.Lys593* 10748197:122:228
status: NEW
PMID: 10933805
[PubMed]
King SA et al: "R-domain interactions with distal regions of CFTR lead to phosphorylation and activation."
No.
Sentence
Comment
27
1 Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ABC, ATP binding cassette; NBD, nucleotide binding domain; TMD, transmembrane domain; R-domain, regulatory domain; PKA, cyclic AMP-dependent protein kinase A; His P, NBD of histidine permease; His Q and His M, TMDs of histidine permease; Mal K, NBD region of the maltose transport system; Mal F, integral membrane protein of the maltose transport system; AMP, adenosine monophosphate; ∆R-CFTR, CFTR lacking amino acids 708-835; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; DMEM, Dulbecco`s Modified Eagle`s Medium; FBS, fetal bovine serum; vTF7.3, vaccina virus encoding the T7 polymerase; MOI, multiplicity of infection; DOC, deoxycholic acid; PVDF, poly- (vinylidene difluoride); NBT, 4-nitroblue tetrazolium chloride; SPQ, 6-methoxy-N-(3-sulfopropyl)quinolonium; BCIP, 5-bromo-4-chloro-3-indolyl phosphate; -gal, -galactosidase; ∆1-836, carboxy hemi-CFTR beginning immediately after the R-domain; M837X, CFTR truncation that ends at CFTR position 836, after the R-domain; G723X, CFTR truncation ending at residue 722 within the R-domain; K593X, CFTR truncation ending immediately before the R-domain at position 592.
X
ABCC7 p.Lys593* 10933805:27:1176
status: NEW179 K593X (CFTR truncated immediately before the R-domain, Table 1) co-immunoprecipitated with ∆1-836 in a manner similar to that of M837X or G723X (data not shown), but coexpression of K593X with ∆1-836 failed to produce enhanced halide efflux (Figure 8A).
X
ABCC7 p.Lys593* 10933805:179:0
status: NEWX
ABCC7 p.Lys593* 10933805:179:189
status: NEW228 FIGURE 8: G723X coexpression with ∆1-836 produces enhanced halide efflux, while K593X does not.
X
ABCC7 p.Lys593* 10933805:228:87
status: NEW229 (A) G723X and ∆1-836 (9) or K593X and ∆1-836 (b) were expressed in COS7 cells, and halide efflux was assayed as described in the legend of Figure 5.
X
ABCC7 p.Lys593* 10933805:229:35
status: NEW231 K593X, missing the complete R-domain, failed to increase halide permeability when coexpressed with ∆1-836.
X
ABCC7 p.Lys593* 10933805:231:0
status: NEW
PMID: 9922379
[PubMed]
Schwiebert EM et al: "CFTR is a conductance regulator as well as a chloride channel."
No.
Sentence
Comment
416
Cystic fibrosis transmembrane con- when a truncated CFTR construct that contains a functioning NBF1 (K593X) was expressed with ROMK2, Ç50%ductance regulator could be coupled with either ROMK1 or ROMK2 in the cell membrane, providing a missing of K/ current was glibenclamide sensitive, demonstrating a significant but not complete inhibition (130).
X
ABCC7 p.Lys593* 9922379:416:101
status: NEW418 Alternatively, the mechanism that con- ROMK2 and K593X/ROMK2 data suggest that the interaction between CFTR and ROMK2 may require a functionaltrols the CFTR-ROMK2 interaction could involve a regulatory protein or a cytoskeletal element.
X
ABCC7 p.Lys593* 9922379:418:49
status: NEW
PMID: 9374850
[PubMed]
McNicholas CM et al: "A functional CFTR-NBF1 is required for ROMK2-CFTR interaction."
No.
Sentence
Comment
13
In oocytes coinjected with ROMK2 and a truncated construct of CFTR with an intact NBF1 (CFTR-K593X), glibenclamide inhibited Kϩ currents by 46%.
X
ABCC7 p.Lys593* 9374850:13:93
status: NEW69 The oligonucleotides used for mutagenesis were CFTR-G551D:5Ј GAGTGGAGAT- CAACGAG 3Ј, CFTR-A455E:5Ј GTTGTTGGAGGTTGCTGG 3Ј, CFTR-K370X:5Ј GCAATAAACTAAATACAGGATATCTTAC 3Ј, and CFTR-K593X:5Ј CTGTTAACTGATGGCTAGCAAACTAGG 3Ј.
X
ABCC7 p.Lys593* 9374850:69:214
status: NEW84 To test our hypothesis, we measured the glibenclamide sensitivity of the Kϩ currents (using the experimental protocol described above) when ROMK2 was coexpressed with two engineered CFTR-mutant constructs, CFTR-K593X or CFTR-K370X, or two naturally occurring CFTR-mutant constructs, CFTR-G551D or CFTR-A455E (see Fig. 2).
X
ABCC7 p.Lys593* 9374850:84:27
status: NEWX
ABCC7 p.Lys593* 9374850:84:217
status: NEW87 In our initial experiments with the mutant CFTR constructs, we coexpressed ROMK2 with either CFTR truncated after NBF1 (CFTR-K593X, Fig. 2) or CFTR truncated before NBF1 (CFTR-K370X, Fig. 2).
X
ABCC7 p.Lys593* 9374850:87:125
status: NEW88 Similar to the effect observed with the coexpression of wild-type CFTR and ROMK2, coexpressing ROMK2:CFTR-K593X elicited Ba2ϩ-sensitive currents that were decreased by 45.8 Ϯ 8.1% (n ϭ 8) after the oocytes were exposed to glibenclamide (Figs.
X
ABCC7 p.Lys593* 9374850:88:8
status: NEWX
ABCC7 p.Lys593* 9374850:88:106
status: NEW92 Therefore, the mutant CFTR-K593X is similar to CFTR-WT in conferring glibenclamide sensitivity on ROMK2.
X
ABCC7 p.Lys593* 9374850:92:27
status: NEW93 Because mutant CFTR-K593X is a truncated version of CFTR-WT that lacks the latter half of the protein [including the regulatory (R) and NBF2 domains, as well as transmembrane regions 7-12 (see Fig. 2)], this portion of the Fig. 2.
X
ABCC7 p.Lys593* 9374850:93:20
status: NEW96 B: CFTR-K593X, a mutant truncated at residue 593, has an intact NBF1.
X
ABCC7 p.Lys593* 9374850:96:8
status: NEW102 When ROMK2 and CFTR-K370X were coexpressed, the observed Ba2ϩ- sensitive Kϩ currents decreased by only 12.3 Ϯ 3.3% (n ϭ 12) after oocytes were exposed to glibenclamide.
X
ABCC7 p.Lys593* 9374850:102:144
status: NEW107 This minimal reduction in the Ba2ϩ-sensitive current following glibenclamide treatment was significantly less than that observed when ROMK2 was coexpressed with CFTR-WT (P ϭ 0.013, Fig. 1) or with CFTR-K593X (P ϭ 0.013, Fig. 3A) but similar to that observed when ROMK2 was expressed alone (P ϭ 0.73, Fig. 4).
X
ABCC7 p.Lys593* 9374850:107:214
status: NEW110 Sensitivity of CFTR Cl- currents to glibenclamide Construct Whole Cell Current, nA %Inhibition By Glibenclamide n P CFTR-WT 560Ϯ150 51.9 9 CFTR-K593X 190Ϯ31 50.1 8 NS CFTR-K370X 183Ϯ85 44.1 5 NS CFTR-G551D 334Ϯ80 49.6 7 NS CFTR-A455E 299Ϯ27 63.2 5 NS Uninjected 26Ϯ10 0 5 0.02 Values are means Ϯ SE; n is no. of experiments.
X
ABCC7 p.Lys593* 9374850:110:150
status: NEW120 Effect of glibenclamide on Ba2ϩ-sensitive currents for ROMK2 coexpressed with CFTR mutants CFTR-K593X and CFTR-G551D.
X
ABCC7 p.Lys593* 9374850:120:102
status: NEWX
ABCC7 p.Lys593* 9374850:120:197
status: NEW121 Time course showing whole cell currents at Vhold ϭ -60 mV for Xenopus oocytes expressing ROMK2:CFTR-K593X (A) and ROMK2: CFTR-G551D (B) obtained using 2-microelectrode voltage-clamp techniques.
X
ABCC7 p.Lys593* 9374850:121:106
status: NEW128 Average Ba2ϩ-sensitive whole cell currents for each condition are as follows: ROMK2 alone ϭ 11.35 Ϯ 3.3 µA, ROMK2:CFTR-WT ϭ 8.29 Ϯ 0.9 µA, ROMK2:CFTR-G551D ϭ 5.57 Ϯ 0.66 µA, ROMK2:CFTR-K593X ϭ 2.37 Ϯ 0.7 µA, ROMK2: A455E ϭ 6.26 Ϯ 1.39 µA, and ROMK2:K370X ϭ 5.57 Ϯ 0.66 µA. A455E (Fig. 2).
X
ABCC7 p.Lys593* 9374850:128:242
status: NEW7 In oocytes coinjected with ROMK2 and a truncated construct of CFTR with an intact NBF1 (CFTR-K593X), glibenclamide inhibited K1 currents by 46%.
X
ABCC7 p.Lys593* 9374850:7:93
status: NEW62 The oligonucleotides used for mutagenesis were CFTR-G551D:58 GAGTGGAGAT- CAACGAG 38, CFTR-A455E:58 GTTGTTGGAGGTTGCTGG 38, CFTR-K370X:58 GCAATAAACTAAATACAGGATATCTTAC 38, and CFTR-K593X:58 CTGTTAACTGATGGCTAGCAAACTAGG 38.
X
ABCC7 p.Lys593* 9374850:62:178
status: NEW77 To test our hypothesis, we measured the glibenclamide sensitivity of the K1 currents (using the experimental protocol described above) when ROMK2 was coexpressed with two engineered CFTR-mutant constructs, CFTR-K593X or CFTR-K370X, or two naturally occurring CFTR-mutant constructs, CFTR-G551D or CFTR-A455E (see Fig. 2).
X
ABCC7 p.Lys593* 9374850:77:211
status: NEW80 In our initial experiments with the mutant CFTR constructs, we coexpressed ROMK2 with either CFTR truncated after NBF1 (CFTR-K593X, Fig. 2) or CFTR truncated before NBF1 (CFTR-K370X, Fig. 2).
X
ABCC7 p.Lys593* 9374850:80:125
status: NEW81 Similar to the effect observed with the coexpression of wild-type CFTR and ROMK2, coexpressing ROMK2:CFTR-K593X elicited Ba21-sensitive currents that were decreased by 45.8 6 8.1% (n 5 8) after the oocytes were exposed to glibenclamide (Figs. 3A and 4).
X
ABCC7 p.Lys593* 9374850:81:106
status: NEW85 Because mutant CFTR-K593X is a truncated version of CFTR-WT that lacks the latter half of the protein [including the regulatory (R) and NBF2 domains, as well as transmembrane regions 7-12 (see Fig. 2)], this portion of the Fig. 2.
X
ABCC7 p.Lys593* 9374850:85:20
status: NEW99 This minimal reduction in the Ba21-sensitive current following glibenclamide treatment was significantly less than that observed when ROMK2 was coexpressed with CFTR-WT (P 5 0.013, Fig. 1) or with CFTR-K593X (P 5 0.013, Fig. 3A) but similar to that observed when ROMK2 was expressed alone (P 5 0.73, Fig. 4).
X
ABCC7 p.Lys593* 9374850:99:202
status: NEW112 Effect of glibenclamide on Ba21-sensitive currents for ROMK2 coexpressed with CFTR mutants CFTR-K593X and CFTR-G551D.
X
ABCC7 p.Lys593* 9374850:112:96
status: NEW113 Time course showing whole cell currents at Vhold 5 260 mV for Xenopus oocytes expressing ROMK2:CFTR-K593X (A) and ROMK2: CFTR-G551D (B) obtained using 2-microelectrode voltage-clamp techniques.
X
ABCC7 p.Lys593* 9374850:113:100
status: NEW